JohnPKueblerMD

Oncology • Columbus, OH

Medical Oncology Specialist in Columbus, Ohio.

Join to view full profile

Dr. Kuebler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kuebler's full profile

Already have an account?

Office
810 Jasonway Ave
Ste A
Columbus, OH 43214
Phone+1 614-442-3130

Fax+1 614-442-3145
Is this information wrong?

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1980 - 1983
Case Western Reserve University/University Hospitals Cleveland Medical CenterInternship, Internal Medicine, 1977 - 1978
Case Western Reserve University School of MedicineClass of 1977

Certifications & Licensure

OH State Medical License 1979 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Start of enrollment: 2008 Feb 25
Active, not recruiting
Phase 2
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Start of enrollment: 2008 Mar 01
Active, not recruiting
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Start of enrollment: 2009 Sep 01
Recruiting
Phase 3
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Start of enrollment: 2010 Apr 05
Active, not recruiting
Phase 3
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Start of enrollment: 2010 Mar 15
Active, not recruiting
Phase 1, Phase 2
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer Start of enrollment: 2011 Nov 01
Completed
Not Applicable
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Active, not recruiting
Phase 3
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
Active, not recruiting
Phase 3
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
Completed
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia Start of enrollment: 2012 Jun 18
Completed
Phase 3
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer Start of enrollment: 2012 Jul 01
Completed
Phase 2
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
Active, not recruiting
Phase 3
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Start of enrollment: 2013 May 15
Completed
Phase 3
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Completed
Phase 1, Phase 2
Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Start of enrollment: 2012 Nov 01
Completed
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2013 Jan 18
Active, not recruiting
Phase 2
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery Start of enrollment: 2013 Aug 01
Active, not recruiting
Not Applicable
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma Start of enrollment: 2013 Oct 01
Completed
Phase 2
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24
Active, not recruiting
Phase 2
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Start of enrollment: 2014 Feb 01
Completed
Phase 2
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Active, not recruiting
Phase 3
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17
Active, not recruiting
Phase 2, Phase 3
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Start of enrollment: 2014 Feb 27
Active, not recruiting
Phase 2, Phase 3
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Start of enrollment: 2014 Mar 29
Active, not recruiting
Phase 3
S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer Start of enrollment: 2014 May 01
Terminated
Phase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) Start of enrollment: 2015 Feb 11
Active, not recruiting
Phase 3
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Sep 19
Active, not recruiting
Phase 2
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer Start of enrollment: 2015 May 07
Active, not recruiting
Phase 2, Phase 3
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Recruiting
Phase 3
High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Start of enrollment: 2015 Nov 10
Active, not recruiting
Phase 3
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Start of enrollment: 2016 Jan 06
Completed
Phase 2
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed Start of enrollment: 2016 Apr 05
Active, not recruiting
Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

31 citations
Effects of a Home-based Exercise Program on Anxiety and Mood Disturbances in Older Adults with Cancer Receiving Chemotherapy.
Kah Poh Loh, Ian R. Kleckner, Po-Ju Lin, Supriya G. Mohile, Beverly Canin, Marie Flannery, Chunkit Fung, Richard F. Dunne, Javier Bautista, Eva Culakova, Amber S. Klec...> ;Journal of the American Geriatrics Society. 2019 May 1
30 citations
Effects of exercise on inflammation in patients receiving chemotherapy: a nationwide NCORP randomized clinical trial.
Ian R. Kleckner, Charles Kamen, Calvin L. Cole, Chunkit Fung, Charles E. Heckler, Joseph J. Guido, Eva Culakova, Adedayo A. Onitilo, Alison Conlin, J. Philip Kuebler, ...> ;Supportive Care in Cancer. 2019 Apr 2
20 citations
Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer
Balazs Halmos, Nathan A. Pennell, Pingfu Fu, Shumaila Saad, Shirish M. Gadgeel, Gregory A. Otterson, Tarek Mekhail, Michael R. Snell, J. Philip Kuebler, Neelesh Sharma...> ;The Oncologist. 2015 Nov 1
12 citations
Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer
Steven R. Alberts, Tiffany M. Yu, Robert J. Behrens, Lindsay A. Renfro, Geetika Srivastava, Gamini S. Soori, Shaker R. Dakhil, Rex B. Mowat, John P. Kuebler, George P....> ;Pharmacoeconomics. 2014 Aug 26
44 citations
Prospective Multicenter Study of the Impact of Oncotype DX Colon Cancer Assay Results on Treatment Recommendations in Stage II Colon Cancer Patients
Geetika Srivastava, Lindsay A. Renfro, Robert J. Behrens, Margarita Lopatin, Calvin Chao, Gamini S. Soori, Shaker R. Dakhil, Rex B. Mowat, J. Philip Kuebler, George P....> ;The Oncologist. 2014 May 1
48 citations
Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy.
Joseph A. Roscoe, Charles E. Heckler, Gary R. Morrow, Supriya G. Mohile, Shaker R. Dakhil, James L. Wade, J. Philip Kuebler> ;Journal of Clinical Oncology. 2012 Sep 20
456 citations
Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses
Greg Yothers, Michael J. O'Connell, Carmen J. Allegra, J. Philip Kuebler, Linda H. Colangelo, Nicholas J. Petrelli, Norman Wolmark> ;Journal of Clinical Oncology. 2011 Oct 1
Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR TKI-responsive, advanced non-small ...
Halmos B, Fu P, Pennell NA, Otterson GA, Mekhail T, Snell MR, Kuebler JP, Gadgeel SM, Conrad A, Stefanski AT, Dowlati A> ;J. Clin. Oncol.. 2011-05-20
12 citations
Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer
Bhuvaneswari Ramaswamy, Ewa Mrozek, John Philip Kuebler, Tanios Bekaii-Saab, Eric H. Kraut> ;Investigational New Drugs. 2011 Apr 1
4 citations
Radioembolization of liver metastases in patients with colorectal cancer: a nonsurgical treatment with combined modality potential.
J. Philip Kuebler> ;Journal of Clinical Oncology. 2009 Sep 1
361 citations
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124
Primo N. Lara, Ronald B. Natale, John Crowley, Heinz-Josef Lenz, Mary W. Redman, Jane E. Carleton, James R. Jett, Corey J. Langer, J. Philip Kuebler, Shaker R. Dakhil,...> ;Journal of Clinical Oncology. 2009 May 20
29 citations
Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospect...
J. Philip Kuebler, Linda H. Colangelo, Michael J. O'Connell, Roy E. Smith, Greg Yothers, Mirsada Begovic, Bridget A. Robinson, Thomas E. Seay, Norman Wolmark> ;Cancer. 2007 Nov 1
744 citations
Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07
J. Philip Kuebler, H. Samuel Wieand, Michael O’Connell, Roy E. Smith, Linda H. Colangelo, Greg Yothers, N. J. Petrelli, Michael Findlay, Thomas E. Seay, James N. Atkin...> ;Journal of Clinical Oncology. 2007 Jun 1
34 citations
Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncol...
Wolfram E. Samlowski, James J. Moon, J. Philip Kuebler, Craig R. Nichols, David R. Gandara, Howard Ozer, Stephen K. Williamson, James N. Atkins, David E. Schuller, Joh...> ;Cancer Investigation. 2007 Apr 1
20 citations
Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Projec...
James N. Atkins, Samuel A. Jacobs, H. Samuel Wieand, Roy E. Smith, William J. John, Linda H. Colangelo, Victor G. Vogel, J. Philip Kuebler, Terrence P. Cescon, Barbara...> ;Clinical Colorectal Cancer. 2005 Sep 1
Phase II study of CI-958 in patients with hormone refractory prostate carcinoma.
J. Philip Kuebler, Timothy Moore, James Pritchard, Eric H. Kraut> ;Investigational New Drugs. 2004 Apr 1
9 citations
Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer.
J. Philip Kuebler, Aimery de Gramont> ;Seminars in Oncology. 2003 Oct 1
273 citations
Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504
David R. Gandara, Kari Chansky, Kathy S. Albain, Bryan R. Leigh, Laurie E. Gaspar, Primo N. Lara, Howard Burris, Paul H. Gumerlock, J. Philip Kuebler, James D. Bearden...> ;Journal of Clinical Oncology. 2003 May 15
5 citations
Phase II study of pyrazoloacridine in metastatic renal cell carcinoma.
J P Kuebler, G W King, P Triozzi, Timothy Moore, Eric H. Kraut> ;Investigational New Drugs. 2001 Jan 1
19 citations
Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group phase II study.
Wolfram E. Samlowski, Holly Gundacker, J. Philip Kuebler, Jeffrey K. Giguere, Glenn Mills, David E. Schuller, John F. Ensley> ;Investigational New Drugs. 2001 Jan 1
A phase II trial of topotecan in esophageal carcinoma: a Southwest Oncology Group study (SWOG 9339).
Macdonald JS, Jacobson JL, Ketchel SJ, Weiss G, Taylor S, Mills G, Kuebler JP, Rivkin S, Conrad M> ;Invest New Drugs. 2000-05-01
4 citations
Phase II study of edatrexate in advanced head and neck cancer
J. Philip Kuebler, Jacqueline Benedetti, David E. Schuller, John F. Ensley, Steven M. Grunberg, Michael J. Muirhead, Kathryn E. Richert-Boe, Manly E. Marshall> ;Investigational New Drugs. 1994 Dec 1
7 citations
Treatment of Metastatic Renal Cell Carcinoma with Recombinant Interleukin-2 in Combination with Vinblastine or Lymphokine-Activated Killer Cells
J. Philip Kuebler, Robert P. Whitehead, David L. Ward, George P. Hemstreet, Edward C. Bradley> ;The Journal of Urology. 1993 Sep 1
4 citations
A phase II study of chemotherapy of metastatic colorectal carcinoma with 5-fluorouracil plus cisplatin. A Southwest Oncology Group study.
Robert P. Whitehead, Thomas R. Fleming, Frederick R. Ahmann, Harinder S. Garewal, J. Philip Kuebler> ;Investigational New Drugs. 1991 Nov 1
Phase II study of fazarabine in advanced head and neck cancer. A Southwest Oncology Group study.
Kuebler JP, Metch B, Schuller DE, Keppen M, Hynes HE> ;Invest New Drugs. 1991-11-01
Join now to see all

Hospital Affiliations

OhioHealth Riverside Methodist HospitalColumbus, Ohio